Skip to main content
. 2020 Jul 24;12:1758835920936089. doi: 10.1177/1758835920936089

Table 5.

Recent clinical trials with immune checkpoint inhibitors in mCRC.

Trial Phase Treatment MSI/MSS status N° patients ORR (%) PFS OS
KEYNOTE 016
Le 2015
II Pembrolizumab Refractory MSI high mCRC
Refractory MSS mCRC
41(32 mCRC) 40
0
NR
2.2 months
NR
5 months
KEYNOTE 164 II Pembrolizumab Refractory MSI mCRC 63 32 4.1 76% (12m)
NCT02375672 II Pembrolizumab + FOLFOX 1° line mCRC (3% MSI) 30 53
Checkmate 142 II Nivolumab
Nivolumab+ ipilimumab
Refractory MSI mCRC 74
119
31.1
55
50% (12 months)
71% (12 months)
73% (12 months)
85% (12 months)
COTEZO IMblaze370 III Atezolizumab versus
cobimetinib/atezolizumab versus
regorafenib
Refractory MSS and MSI mCRC 90
183
90
-
2.7
-
- 7.1
8.87
8.5
CCTG CO.26 Durvalumab/tramelimumab versus BSC Refractory MSS mCRC 6.6 versus 4.1
p = 0.07
REGONIVO Ib Regorafenib + nivolumab 33% MSS mCRC 36
NCT02860546 II TAS102 + nivolumab MSS mCRC 18 0 2.8

mCRC, metastatic colorectal cancer; mOS, median overall survival; mPFS, median progression free survival; MSI, microsatellite instability; MSS, microsatellite stability; ORR, overall response rate.